Effect of chronic hepatitis C on the activity of the membrane transporters P‐gp and OATP1B1/BCRP on patients with different stages of hepatic fibrosis (2023)
- Authors:
- USP affiliated authors: ROCHA, ADRIANA - FCFRP ; PEREIRA, MARIA PAULA MARQUES - FCFRP ; REZENDE, ROSAMAR EULIRA FONTES - FMRP ; LANCHOTE, VERA LUCIA - FCFRP
- Unidades: FCFRP; FMRP
- DOI: 10.1002/cpt.2908
- Subjects: ANTIVIRAIS; INTERAÇÃO DE MEDICAMENTOS; HEPATITE C; HEPATITE CRÔNICA; GLICOPROTEÍNAS DA MEMBRANA; ANTILIPÊMICOS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Journal of Clinical Pharmacy and Therapeutics
- ISSN: 0009-9236
- Volume/Número/Paginação/Ano: v. 114, n. 1, p. 173-181, 2023
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
PIPPA, Leandro Francisco et al. Effect of chronic hepatitis C on the activity of the membrane transporters P‐gp and OATP1B1/BCRP on patients with different stages of hepatic fibrosis. Journal of Clinical Pharmacy and Therapeutics, v. 114, n. 1, p. 173-181, 2023Tradução . . Disponível em: https://doi.org/10.1002/cpt.2908. Acesso em: 17 fev. 2026. -
APA
Pippa, L. F., Vieira, C. P., Caris, J. A., Rocha, A., Marques, M. P., Garcia, C. P., et al. (2023). Effect of chronic hepatitis C on the activity of the membrane transporters P‐gp and OATP1B1/BCRP on patients with different stages of hepatic fibrosis. Journal of Clinical Pharmacy and Therapeutics, 114( 1), 173-181. doi:10.1002/cpt.2908 -
NLM
Pippa LF, Vieira CP, Caris JA, Rocha A, Marques MP, Garcia CP, Rezende REF, Lanchote VL. Effect of chronic hepatitis C on the activity of the membrane transporters P‐gp and OATP1B1/BCRP on patients with different stages of hepatic fibrosis [Internet]. Journal of Clinical Pharmacy and Therapeutics. 2023 ; 114( 1): 173-181.[citado 2026 fev. 17 ] Available from: https://doi.org/10.1002/cpt.2908 -
Vancouver
Pippa LF, Vieira CP, Caris JA, Rocha A, Marques MP, Garcia CP, Rezende REF, Lanchote VL. Effect of chronic hepatitis C on the activity of the membrane transporters P‐gp and OATP1B1/BCRP on patients with different stages of hepatic fibrosis [Internet]. Journal of Clinical Pharmacy and Therapeutics. 2023 ; 114( 1): 173-181.[citado 2026 fev. 17 ] Available from: https://doi.org/10.1002/cpt.2908 - Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: focus on veterinary clinical pharmacokinetics
- Suppression of CYP isoforms in patients with chronic hepatitis c before and after pharmacological treatment depends on the stage of hepatic fibrosis
- Simultaneous analysis of the total plasma concentration of atorvastatin and its five metabolites and the unbound plasma concentration of atorvastatin: application in a clinical pharmacokinetic study of single oral dose
- Influence of gasoline inhalation on the enantioselective pharmacokinetics of fluoxetine in rats
- Analysis of ibuprofen enantiomers in rat plasma by liquid chromatography with tandem mass spectrometry
- Impact of Plasmodium vivax malaria and antimalarial treatment on cytochrome P450 activity in Brazilian patients
- Total, unbound, renal, and hepatic clearances of raltegravir and the formation and elimination clearances of raltegravir glucuronide in pregnant Women
- Relação da mutação pré-core G1896A do vírus da hepatite B (HBV) com genótipo viral, níveis séricos de HBV-DNA, expressão tecidual do antígeno core e agressão hepática em pacientes com hepatite B crônica
- P-Glycoprotein and organic anion transporter polypeptide 1B/breast cancer resistance protein drug transporter activity in pregnant women living with HIV
- Pharmacokinetics of venlafaxine enantiomers and their metabolites in psoriasis patients
Informações sobre o DOI: 10.1002/cpt.2908 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003241849.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
